The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
nivolumab and relatlimab-rmbw · Injection
1 marketed package NDCs · 1 active manufacturer
Same drug class
Other molecules FDA puts in Programmed Death Receptor-1 Blocking Antibody, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- atezolizumab and hyaluronidase-tqjs· 1 maker
- nivolumab and hyaluronidase-nvhy· 1 maker
- pembrolizumab and berahyaluronidase alfa-pmph· 1 maker
- retifanlimab-dlwr· 1 maker
- toripalimab-tpzi· 1 maker
- atezolizumab· 2 makers
- dostarlimab· 2 makers
- tislelizumab-jsgr· 2 makers
- pembrolizumab· 5 makers
- nivolumab· 6 makers
Common questions
- Is Nivolumab and relatlimab-rmbw in shortage right now?
- No. FDA does not currently list Nivolumab and relatlimab-rmbw in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Nivolumab and relatlimab-rmbw?
- 1 company has marketed Nivolumab and relatlimab-rmbw in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.